BACKGROUND: Parenteral polymyxin use declined after the 1960s, due to safety concerns. An increase in multidrug-resistant (MDR) gram-negative infections and a shortage of new agents have prompted increased use of parenteral polymyxin. OBJECTIVE: To describe our clinical experience with parenteral polymyxin B for MDR gram-negative bacteremia and urinary tract infection (UTI). METHODS: Paper pharmacy records were used to identify patients aged 18 years or older, presence of MDR gram-negative bacteremia or UTI, and use of parenteral polymyxin B for at least 48 hours. Electronic and paper patient records were then retrospectively reviewed. Polymyxin B susceptibility was evaluated using the Kirby-Bauer method. MDR isolates were defined as resistant to at least 3 antimicrobial classes, excluding polymyxin B. Microbiologic clearance was defined by 1 repeat urine or 2 repeat blood cultures that were sterile or growing different organisms. Secondary outcomes included hospital mortality and nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or more, or a 50% reduction in creatinine clearance. RESULTS: Seventeen infections in 16 patients were treated with polymyxin B (1 pt. had 2 infections that were analyzed separately). Microbiologic clearance occurred in 14 of 16 (88%) cases of MDR gram-negative bacteremia or UTI in which repeat cultures were done. Ten of 16 patients died (all-cause mortality 63%). Five patients required hemodialysis prior to polymyxin B use. Six (55%) of the remaining 11 patients with baseline renal insufficiency developed nephrotoxicity, and none of them required hemodialysis. The mean +/- SD number of days from the initiation of therapy to the onset of nephrotoxicity was 7.5 +/- 2.3 (range 4-10) days. Three (50%) of 6 patients with nephrotoxicity died. CONCLUSIONS: Our data suggest that polymyxin B may be effective for MDR gram-negative infections in patients with limited therapeutic options, but precautions should be taken to avoid toxicity.
BACKGROUND: Parenteral polymyxin use declined after the 1960s, due to safety concerns. An increase in multidrug-resistant (MDR) gram-negative infections and a shortage of new agents have prompted increased use of parenteral polymyxin. OBJECTIVE: To describe our clinical experience with parenteral polymyxin B for MDR gram-negative bacteremia and urinary tract infection (UTI). METHODS: Paper pharmacy records were used to identify patients aged 18 years or older, presence of MDR gram-negative bacteremia or UTI, and use of parenteral polymyxin B for at least 48 hours. Electronic and paper patient records were then retrospectively reviewed. Polymyxin B susceptibility was evaluated using the Kirby-Bauer method. MDR isolates were defined as resistant to at least 3 antimicrobial classes, excluding polymyxin B. Microbiologic clearance was defined by 1 repeat urine or 2 repeat blood cultures that were sterile or growing different organisms. Secondary outcomes included hospital mortality and nephrotoxicity, defined as an increase in serum creatinine of 0.5 mg/dL or more, or a 50% reduction in creatinine clearance. RESULTS: Seventeen infections in 16 patients were treated with polymyxin B (1 pt. had 2 infections that were analyzed separately). Microbiologic clearance occurred in 14 of 16 (88%) cases of MDR gram-negative bacteremia or UTI in which repeat cultures were done. Ten of 16 patients died (all-cause mortality 63%). Five patients required hemodialysis prior to polymyxin B use. Six (55%) of the remaining 11 patients with baseline renal insufficiency developed nephrotoxicity, and none of them required hemodialysis. The mean +/- SD number of days from the initiation of therapy to the onset of nephrotoxicity was 7.5 +/- 2.3 (range 4-10) days. Three (50%) of 6 patients with nephrotoxicity died. CONCLUSIONS: Our data suggest that polymyxin B may be effective for MDR gram-negative infections in patients with limited therapeutic options, but precautions should be taken to avoid toxicity.
Authors: Kady Phe; Yuman Lee; Patrick M McDaneld; Nishant Prasad; Taijun Yin; Deborah A Figueroa; William L Musick; Jessica M Cottreau; Ming Hu; Vincent H Tam Journal: Antimicrob Agents Chemother Date: 2014-02-24 Impact factor: 5.191
Authors: Yanina Dubrovskaya; Ting-Yi Chen; Marco R Scipione; Diana Esaian; Michael S Phillips; John Papadopoulos; Sapna A Mehta Journal: Antimicrob Agents Chemother Date: 2013-08-19 Impact factor: 5.191
Authors: Michael J Satlin; Christine J Kubin; Jill S Blumenthal; Andrew B Cohen; E Yoko Furuya; Stephen J Wilson; Stephen G Jenkins; David P Calfee Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Mohammad A K Azad; Ben A Finnin; Anima Poudyal; Kathryn Davis; Jinhua Li; Prue A Hill; Roger L Nation; Tony Velkov; Jian Li Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Jenisha Ghimire; Shantanu Guha; Benjamin J Nelson; Lisa A Morici; William C Wimley Journal: J Membr Biol Date: 2022-04-18 Impact factor: 2.426
Authors: Mohammad A K Azad; Sivashangarie Sivanesan; Jiping Wang; Ke Chen; Roger L Nation; Philip E Thompson; Kade D Roberts; Tony Velkov; Jian Li Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191